Medication info

Gyeongboranidine Tablet 150 mg (Ranitidine Hydrochloride)

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Ranitidine Hydrochloride›168mg / 1 tablet
Manufacturer / importer
Gyeongbo Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
100 tablets (10 tablets/PTP*10)
Approval status
Approval withdrawn

MFDS item code 200403722 · Notified 2004.06.23

This product's status changed to Approval withdrawn on 2023.09.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of acid-related disorders (ulcers, esophagitis, etc.), improvement of gastric mucosal lesions, prevention of Mendelson syndrome
Who takes it
Adults · Children
Adult dose
Administer ranitidine 150 mg orally twice daily, in the morning and at bedtime. Gastric and duodenal ulcers: Administer 150 mg of this medicine orally twice daily, or 300 mg once daily at bedtime. In particular, a higher healing rate may be achieved in patients with duodenal ulcer by administering 300 mg twice daily, in the morning and at bedtime. The same dosage regimen applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for prevention of gastric and duodenal ulcers during long-term administration of nonsteroidal anti-inflammatory drugs. Healing usually occurs within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer depending on the patient. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. Reflux esophagitis: Administer 150 mg of this medicine twice daily for 8 weeks, or 300 mg once daily at bedtime. For patients with severe reflux esophagitis, the dose may be increased to 150 mg 4 times daily. Zollinger-Ellison syndrome: Initiate treatment with an initial dose of 150 mg of this medicine 3 times daily; the dose may be increased as necessary. In severe cases, up to 6 g daily may be administered as directed by a physician. Upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer, and acute gastric mucosal lesions: Treatment is usually initiated with an injectable formulation; once oral administration is possible, switch to oral administration of 150 mg of this medicine twice daily. Preanesthetic medication (prevention of Mendelson syndrome): Administer 150 mg of this medicine 2 hours before induction of anesthesia. It is preferable to also administer 150 mg on the night before surgery. Improvement of gastric mucosal lesions (erosion, bleeding, erythema, edema) in acute gastritis or during acute exacerbation of chronic gastritis: Administer 150 mg of this medicine once daily at bedtime. In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the medicine; therefore, readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.
Child dose
Patients 12 years and older: Administer 75 mg orally twice daily (liquid formulation only). Ages 8 〜 18 years: 150 mg per dose (2 mg per kg of body weight) may be administered up to twice daily.

Ingredients

Manufacturer
Gyeongbo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (ulcers, esophagitis, etc.), improvement of gastric mucosal lesions, prevention of Mendelson syndrome

  • Gastric and duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • prevention of Mendelson syndrome
  • postoperative ulcers
  • gastric and duodenal ulcers due to NSAID use
  • gastric mucosal lesions
  • erosion
  • bleeding
  • redness
  • swelling
  • acute gastritis
View approved original text

This medication is primarily effective for the treatment of ulcers in the stomach and duodenum, as well as conditions related to excessive stomach acid such as Zollinger-Ellison syndrome and gastroesophageal reflux disease. It is also used to prevent Mendelson syndrome during preoperative anesthesia, as well as to treat ulcers that may occur due to NSAID use. It helps improve acute and chronic gastritis exacerbation, gastric mucosal erosion, bleeding, redness, and swelling, and is effective when there is upper gastrointestinal bleeding. Additionally, it is used to relieve symptoms of heartburn or acid reflux due to excessive stomach acid. Overall, this medication helps protect the gastric mucosa and promotes the rapid recovery of damaged areas, alleviating the patient's symptoms.

How to take

Adult dose

Administer ranitidine 150 mg orally twice daily, in the morning and at bedtime. Gastric and duodenal ulcers: Administer 150 mg of this medicine orally twice daily, or 300 mg once daily at bedtime. In particular, a higher healing rate may be achieved in patients with duodenal ulcer by administering 300 mg twice daily, in the morning and at bedtime. The same dosage regimen applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for prevention of gastric and duodenal ulcers during long-term administration of nonsteroidal anti-inflammatory drugs. Healing usually occurs within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer depending on the patient. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. Reflux esophagitis: Administer 150 mg of this medicine twice daily for 8 weeks, or 300 mg once daily at bedtime. For patients with severe reflux esophagitis, the dose may be increased to 150 mg 4 times daily. Zollinger-Ellison syndrome: Initiate treatment with an initial dose of 150 mg of this medicine 3 times daily; the dose may be increased as necessary. In severe cases, up to 6 g daily may be administered as directed by a physician. Upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer, and acute gastric mucosal lesions: Treatment is usually initiated with an injectable formulation; once oral administration is possible, switch to oral administration of 150 mg of this medicine twice daily. Preanesthetic medication (prevention of Mendelson syndrome): Administer 150 mg of this medicine 2 hours before induction of anesthesia. It is preferable to also administer 150 mg on the night before surgery. Improvement of gastric mucosal lesions (erosion, bleeding, erythema, edema) in acute gastritis or during acute exacerbation of chronic gastritis: Administer 150 mg of this medicine once daily at bedtime. In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the medicine; therefore, readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.

Child dose

Patients 12 years and older: Administer 75 mg orally twice daily (liquid formulation only). Ages 8 〜 18 years: 150 mg per dose (2 mg per kg of body weight) may be administered up to twice daily.

Precautions

This medication should not be used in patients who have had allergic reactions to this medication or its ingredients. Also, it should not be administered to patients with a history of acute porphyria as it may worsen symptoms. Patients with impaired kidney function should be cautious as this medication can remain in the body longer and lead to side effects, necessitating dosage reduction or increased dosing intervals. Patients with decreased liver function should also be monitored closely. Patients with a history of drug allergies and the elderly should use this medication carefully. Particular caution is necessary for patients taking non-steroidal anti-inflammatory drugs (NSAIDs), and regular health status monitoring is needed. This medication can mask symptoms of gastric cancer, therefore patients with gastric ulcers or those over middle age who have recently developed dyspepsia should confirm the absence of gastric cancer before use. Patients with gastric or duodenal ulcers infected with Helicobacter pylori should undergo eradication therapy. Rarely, severe allergic reactions or shock may occur with this medication, so symptoms should be monitored closely. If symptoms such as hives, rash, breathing difficulties, or hypotension appear, immediately discontinue the medication and consult a physician. Various side effects, including blood disorders, impaired liver function, heart rhythm problems, gastrointestinal disturbances, and neurological symptoms, can occur infrequently, so it is important to report any unusual symptoms immediately. In particular, patients with impaired kidney function may be more susceptible to neurological side effects and should be cautious. If this medication is ineffective, it is advisable to switch to other treatment options, and regular blood, liver, and kidney function tests are recommended for safety. The elderly or patients with chronic lung diseases, diabetes, or weakened immune systems may have an increased risk of pneumonia. If dizziness or drowsiness occurs during treatment, one should avoid driving or operating dangerous machinery. This medication may interact with other drugs, so patients should disclose any medications they are taking. Especially when taken with anticoagulants, blood coagulation status should be frequently checked. Taking high doses of sucralfate concomitantly may reduce absorption, so it's advisable to space doses by more than 2 hours. Pregnant or possibly pregnant women should carefully consider the risks and benefits of using this medication. During breastfeeding, this medication may be transmitted through breast milk, so consultation with a physician is essential before use. Safety in children has not been fully established, therefore caution is needed. Elderly patients are likely to have decreased kidney function, so dosage adjustment and extended dosing intervals may be necessary. This medication may yield false-positive results in urine protein tests, thus adjusting the testing method is advisable. In cases of overdose, vomiting or gastric lavage should be performed to remove the medication, and appropriate treatment should be sought; serious side effects are rare. Keep out of reach of children and avoid transferring to another container. This medication reduces stomach acid secretion, potentially increasing the risk of infections due to bacterial overgrowth, hence caution is warranted. If used long-term, eye-related tests may be required.

Side effects

  • Anaphylactic shock
  • urticaria
  • angioedema
  • rash
  • fever
  • bronchospasm
  • hypotension
  • chest pain
  • granulocytopenia
  • increased serum creatinine
Show 60 more
  • leukopenia
  • thrombocytopenia
  • bone marrow hypoplasia
  • aplastic anemia
  • aplastic anemia
  • refractoriness anemia
  • agranulocytosis
  • pancytopenia
  • acquired immune hemolytic anemia
  • eosinophilia
  • generalized malaise
  • weakness
  • subcutaneous bleeding
  • mucosal bleeding
  • fever
  • liver dysfunction
  • jaundice
  • hepatitis
  • bradycardia
  • heart block
  • tachycardia
  • vasculitis
  • constipation
  • nausea
  • vomiting
  • abdominal distension
  • abdominal pain
  • loss of appetite
  • diarrhea
  • acute pancreatitis
  • dizziness
  • drowsiness
  • convulsions
  • headache
  • heaviness in the head
  • insomnia
  • agitation
  • anxiety
  • mental confusion
  • depression
  • hallucinations
  • blurred vision
  • involuntary movement disorders
  • altered consciousness
  • hepatic cramps
  • gynecomastia
  • excessive lactation
  • erectile dysfunction
  • decreased libido
  • arthralgia
  • myalgia
  • rhabdomyolysis
  • skin rash
  • erythema multiforme
  • alopecia
  • glossitis
  • pruritus
  • mucocutaneous syndrome
  • toxic epidermal necrolysis
  • acute interstitial nephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure and kept at room temperature between 1 degree Celsius and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

100 tablets (10 tablets/PTP*10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.